Drug Prices

In 2014, Ariel Leaty received a frightening diagnosis—acute lymphocytic leukemia. “I went through three years of chemotherapy,” Leaty, 29, of Bloomfield NJ, recalls, “followed by outpatient maintenance.”

The ordeal was grueling, but it would have been far worse, if not deadly, without generic drugs. “If I didn’t have generic prescriptions,” Leaty says, “I probably wouldn’t be here, because the brand-name drugs are expensive—sometimes over $200 a bottle.”

The 10th edition of AAM’s annual generic drug savings and access report, which was released last month, is full of important data for policymakers as well as industry leaders. The report provides detailed information on savings by state, payer type, treatment area, and other factors, as well as the state of the biosimilars market. Here are 10 noteworthy takeaways from the publication.

America’s patients can now see how much they save by treating their health conditions using generic drugs thanks to new data pulled from this year’s Generic Access and Savings Report in the United States.

Keon Torres, 26, of New York, counts on generic medicine to control his ulcerative colitis. He is featured in the recently released tenth edition of the annual generic drug savings and access report.

Here’s Keon’s story, in his own words:

In 2014, Ariel Leaty received a frightening diagnosis—acute lymphocytic leukemia. Leaty, 29, of Bloomfield NJ, is featured in the recently released tenth edition of the annual generic drug savings and access report.

Here’s her story, in her own words: